[4-[(4R,5R)-2-[[[2,6-di(propan-2-yl)phenyl]carbamoylamino]methyl]-4,5-dimethyl-1,3-dioxolan-2-yl]phenyl] dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: [4-[(4R,5R)-2-[[[2,6-di(propan-2-yl)phenyl]carbamoylamino]methyl]-4,5-dimethyl-1,3-dioxolan-2-yl]phenyl] dihydrogen phosphate
• 化学式: C₂₅H₃₅N₂O₇P
• 分子量: 506.5
• InChiKey: WUEHURHTEPWPPO-QZTJIDSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Benzene Compound Having 2 or More Substituents
  申请人：Tamaki Kazuhiko

  公开号：US20080004301A1

  公开（公告）日：2008-01-03

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : —COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R 4 and R 5 : H, optionally substituted alkyl, halogeno, etc.; R 6 and R 7 : H, alkyl; R 8 : —X 2 R 10 [wherein R 10 : —COR 11 (wherein R 11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO 2 R 12 (wherein R 12 : optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X 2 : single bond, optionally substituted alkylene, etc.]; X 1 : —NH—, —O—, —S—, etc.; Y 1 : optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y 2 : optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式(I)如下：[其中R1：-COR9（其中R9：烷基，可选地取代的烷氧基或可选地取代的氨基）；R2：H，OH，烷氧基，可选地取代的氨基等；R3：H，可选地取代的烷基，环烷基，可选地取代的烷氧基，可选地取代的氨基，卤素等；R4和R5：H，可选地取代的烷基，卤素等；R6和R7：H，烷基；R8：-X2R10 [其中R10：-COR11（其中R11：OH，可选地取代的烷氧基，可选地取代的氨基等），-SO2R12（其中R12：可选地取代的烷基，可选地取代的氨基等），四唑-5-基等；X2：单键，可选地取代的烷基等]；X1：-NH-，-O-，-S-等；Y1：可选地取代的苯基，可选地取代的5-至6-成员芳香杂环基；Y2：可选地取代的芳基，可选地取代的杂环基等]。
• MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS
  申请人：Sankyo Company, Limited

  公开号：EP1555032A1

  公开（公告）日：2005-07-20

  [Constitution] A medicinal composition characterized in that an ADP receptor antagonist and an ACAT inhibitor are administered either simultaneously or separately at a defined interval. [Advantage] A medicinal composition, wherein an ADP receptor antagonist and an ACAT inhibitor are administered either simultaneously or separately at a defined interval, is useful as a preventive or a remedy (in particular, a remedy) for arteriosclerosis or diseases derived from arteriosclerosis such as ischemic heart disease, ischemic brain disease and peripheral circulation failure in warm-blooded animals (in particular, humans).

  [章程]一种药物组合物，其特征在于，ADP 受体拮抗剂和 ACAT 抑制剂以规定的间隔同时或分别给药。 [优点]一种药物组合物，其中 ADP 受体拮抗剂和 ACAT 抑制剂以规定的间隔同时或分别给药，可用于预防或治疗（特别是）动脉硬化或动脉硬化引起的疾病，如温血动物（特别是人类）的缺血性心脏病、缺血性脑病和外周循环衰竭。
• BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1806332A1

  公开（公告）日：2007-07-11

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R1: -COR9 (wherein R9: alkyl, optionally substituted alkoxy or optionally substituted amino); R2: H, OH, alkoxy, optionally substituted amino, etc.; R3: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R4 and R5: H, optionally substituted alkyl, halogeno, etc.; R6 and R7: H, alkyl; R8: -X2R10 [wherein R10: -COR11 (wherein R11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), -SO2R12 (wherein R12: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X2: single bond, optionally substituted alkylene, etc.]; X1: -NH-, -O-, -S-, etc.; Y1: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y2: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优异的 LXR 调节剂。由通式（I）代表的化合物： [其中 R1：-COR9（其中 R9：烷基、任选取代的烷氧基或任选取代的氨基）；R2：H、OH、烷氧基、任选取代的氨基等； R3：H、任选取代的烷基、环烷基、任选取代的烷氧基、任选取代的氨基、卤素等； R4 和 R5：H、任选取代的烷基、卤素等。R6和R7：H、烷基；R8：-X2R10[其中 R10：-CORR11（其中 R11：OH、任选取代的烷氧基、任选取代的氨基等）、-SO2R12（其中 R12：任选取代的烷基、任选取代的氨基等）、四唑-5-基等；X2：单键、任选取代的亚烷基等]；X1：-NH-、-O-、-S-等；Y1：任选取代的苯基、任选取代的 5 至 6 元芳香杂环基；Y2：任选取代的芳基、任选取代的杂环基等]等。
• Medicinal composition for treating arteriosclerosis
  申请人：Asai Fumitoshi

  公开号：US20050192245A1

  公开（公告）日：2005-09-01

  A medicinal composition, wherein an ADP receptor antagonist and an ACAT inhibitor are administered either simultaneously or separately at a defined interval as a preventive or a remedy (in particular, a remedy) for arteriosclerosis or diseases derived from arteriosclerosis such as ischemic heart disease, ischemic brain disease and peripheral circulation failure in warm-blooded animals (in particular, humans).

  一种药物组合物，其中 ADP 受体拮抗剂和 ACAT 抑制剂可同时或分别以规定的间隔给药，作为温血动物（尤其是人类）动脉硬化或动脉硬化衍生疾病（如缺血性心脏病、缺血性脑病和外周循环衰竭）的预防或治疗（尤其是治疗）药物。
• US7923573B2
  申请人：——

  公开号：US7923573B2

  公开（公告）日：2011-04-12